Novo Nordisk has been upgraded to a 'Strong Buy' rating following a weak first quarter and a significant drop in its stock price, which now presents an attractive long-term investment opportunity. The company's GLP-1 drugs, including Wegovy and Ozempic, face short-term pricing challenges but are expected to benefit from strong long-term growth despite upcoming price cuts in 2027. Strategic moves like aggressive research and development and the acquisition of Akero position Novo Nordisk well for future differentiation as the obesity market expands. Despite regulatory and competitive risks, the stock is trading below its intrinsic value, making it a compelling buy for investors.
Novo Nordisk reported a 4% sales decline in Q1 FY26 excluding a $4.2B accounting reversal, with key drugs Ozempic and Rybelsus dropping significantly. The company also announced major price cuts for Wegovy and Ozempic in 2027 and faced setbacks with ...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Novo Nordisk has been actively repurchasing its B shares as part of a DKK 15 billion buyback program initiated in February 2026. Since June 15, 2026, the company bought 1.075 million B shares worth approximately DKK 1.78 billion, increasing its treas...
UPS is investing $48 million to enhance 27 temperature-controlled facilities across the Americas, Europe, and Asia to meet rising demand in healthcare logistics. This upgrade aims to improve the handling of temperature-sensitive medicines like GLP-1 ...
Novo Nordisk's Wegovy pill shows three times more prescriptions than rival Zepbound at a similar launch stage, suggesting strong market lead. However, this data excludes significant cash-pay channels where many weight-loss drug users pay out-of-pocke...
